| Trial ID # | NCT02338622 |
| Phase | I |
| Drug Class | Signaling Pathway Inhibitors: PI3K-AKT-mTOR/AKT |
| Drug Name | Capivasertib |
| Alternate Drug Names | AZD5363, Akt inhibitor AZD5363 |
| Drugs in Trial | Olaparib, Capivasertib |
| Eligible Participant | Recurrent ovarian cancer |
| Patients Enrolled | 25 ovarian in dose escalation and dose expansion, median 5 prior therapies (1-12), 16 BRCA MUT |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Efficacy | ORR: 24% (5PR, 1uPR - 3 Pt-S: 2BRCA MUT - 3 Pt-R: 2BRCA MUT, 1PTEN and KRAS and SMARCA4 MUT) |
| Conclusion | Capivasertib+olaparib is safe and tolerable and anti-tumor activity is observed in patients harboring tumors with BRCA MUT and BRCA WT cancers with or without somatic DDR and/or PI3K-AKT pathway alterations |
| Reference | Yap T et al. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2 - and Non-BRCA1/2-Mutant Cancers. Cancer Discov (2020) 10(10):1528-1543 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.